



October 2, 2012

## **NewLink to Present at 3rd Annual Cancer Immunotherapy Conference**

AMES, Iowa, Oct. 2, 2012 /PRNewswire/ -- NewLink Genetics (NASDAQ:NLNK) today announced that the company will be presenting at the 3<sup>rd</sup> Annual *Cancer Immunotherapy: A Long-Awaited Reality* conference taking place from 8:00 a.m. to 6:30 p.m. EDT on October 4, 2012, at the New York Academy of Medicine in New York.

Dr. Charles Link, NewLink's Chairman and Chief Executive Officer, will provide an overview of NewLink. The presentation is expected to begin at 3:45pm ET.

Dr. Link will also participate in a panel session titled "Cancer Vaccines — Past, Present and Future" that will begin at 11:00am ET.

The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the NewLink website at <http://investors.linkp.com/>.

### **About the 3rd Annual Cancer Immunotherapy: A Long-Awaited Reality Conference**

"Cancer Immunotherapy: A Long Awaited Reality" is a unique, single-day conference event that unites founding visionary researchers, clinicians, business leaders, key investors, and other stakeholders to engage in discussions, exchange information, highlight opportunities, and showcase leading companies in the field of cancer immunotherapy.

### **About NewLink Genetics Corporation**

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. NewLink's portfolio includes biologic and small-molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed with an objective to harness multiple components of the innate immune system to combat cancer, either as a monotherapy or in combination with current treatment regimens, without incremental toxicity. NewLink's lead product candidate, HyperAcute® Pancreas cancer immunotherapy (algenpantucel-L) is being studied in a Phase 3 clinical trial in surgically-resected pancreatic cancer patients (patient information is available at <http://www.pancreaticcancer-clinicaltrials.com>). This clinical trial is being performed under a Special Protocol Assessment with the U.S. Food and Drug Administration. NewLink and its collaborators have completed patient enrollment for a Phase 1/2 clinical trial evaluating its HyperAcute® Lung cancer immunotherapy (tergenpumatumucel-L) product candidate for non-small cell lung cancer and a Phase 2 clinical trial for its HyperAcute® Melanoma cancer immunotherapy product candidate. NewLink also is developing indoximod (d-1-methyltryptophan, or D-1MT), a small-molecule, orally bioavailable product candidate from NewLink's proprietary indoleamine-(2,3)-dioxygenase, or IDO, pathway inhibitor technology. Through NewLink's collaboration with the National Cancer Institute, NewLink is studying indoximod in various chemotherapy and immunotherapy combinations in two Phase 1B/2 safety and efficacy clinical trials. For more information please visit [www.linkp.com](http://www.linkp.com).

Contact:  
Gordon Link  
Chief Financial Officer  
515-598-2925  
[glink@linkp.com](mailto:glink@linkp.com)

SOURCE NewLink Genetics Corporation

News Provided by Acquire Media